Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains

被引：0

作者：

机构：

[1] [1,Hay, Duncan A.

[2] 2,Fedorov, Oleg

[3] 2,Martin, Sarah

[4] 2,Singleton, Dean C.

[5] 2,Tallant, Cynthia

[6] 2,Wells, Christopher

[7] Picaud, Sarah

[8] 2,Philpott, Martin

[9] 2,Monteiro, Octovia P.

[10] 2,Rogers, Catherine M.

[11] Conway, Stuart J.

[12] Rooney, Timothy P. C.

[13] 2,Tumber, Anthony

[14] 2,Yapp, Clarence

[15] Filippakopoulos, Panagis

[16] Bunnage, Mark E.

[17] 2,Müller, Susanne

[18] 2,Knapp, Stefan

[19] Schofield, Christopher J.

[20] 2,Brennan, Paul E.

来源：

Brennan, P.E. (paul.brennan@sgc.ox.ac.uk) | 1600年 / American Chemical Society卷 / 136期

关键词：

Small-molecule inhibitors that target bromodomains outside of the bromodomain and extra-terminal (BET) sub-family are lacking. Here; we describe highly potent and selective ligands for the bromodomain module of the human lysine acetyl transferase CBP/p300; developed from a series of 5-isoxazolyl-benzimidazoles. Our starting point was a fragment hit; which was optimized into a more potent and selective lead using parallel synthesis employing Suzuki couplings; benzimidazole-forming reactions; and reductive aminations. The selectivity of the lead compound against other bromodomain family members was investigated using a thermal stability assay; which revealed some inhibition of the structurally related BET family members. To address the BET selectivity issue; X-ray crystal structures of the lead compound bound to the CREB binding protein (CBP) and the first bromodomain of BRD4 (BRD4(1)) were used to guide the design of more selective compounds. The crystal structures obtained revealed two distinct binding modes. By varying the aryl substitution pattern and developing conformationally constrained analogues; selectivity for CBP over BRD4(1) was increased. The optimized compound is highly potent (K d = 21 nM) and selective; displaying 40-fold selectivity over BRD4(1). Cellular activity was demonstrated using fluorescence recovery after photo-bleaching (FRAP) and a p53 reporter assay. The optimized compounds are cell-active and have nanomolar affinity for CBP/p300; therefore; they should be useful in studies investigating the biological roles of CBP and p300 and to validate the CBP and p300 bromodomains as therapeutic targets. © 2014 American Chemical Society;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Journal article (JA)

引用

共 50 条

[21] Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP
Wang, Rui
He, Yupeng
Robinson, Valerie
Yang, Ziping
Hessler, Paul
Lasko, Loren M.
Lu, Xin
Bhathena, Anahita
Lai, Albert
Uziel, Tamar
Lam, Lloyd T.
MOLECULAR CANCER THERAPEUTICS, 2018, 17 (12) : 2543 - 2550
[22] Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells
Uttarkar, Sagar
Piontek, Therese
Dukare, Sandeep
Schomburg, Caroline
Schlenke, Peter
Berdel, Wolfgang E.
Mueller-Tidow, Carsten
Schmidt, Thomas J.
Klempnauer, Karl-Heinz
MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 2905 - 2915
[23] Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors
Lu, Wenchao
Xiong, Huan
Chen, Yu
Wang, Chen
Zhang, Hao
Xu, Pan
Han, Jie
Xiao, Senhao
Ding, Hong
Chen, Zhifeng
Lu, Tian
Wang, Jun
Zhang, Yuanyuan
Yue, Liyan
Liu, Yu-Chih
Zhang, Chenhua
Yang, Yaxi
Jiang, Hualiang
Chen, Kaixian
Zhou, Bing
Luo, Cheng
BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (20) : 5397 - 5407
[24] CBP/p300 Bromodomains Regulate Amyloid-like Protein Aggregation upon Aberrant Lysine Acetylation
Olzscha, Heidi
Fedorov, Oleg
Kessler, Benedikt M.
Knapp, Stefan
La Thangue, Nicholas B.
CELL CHEMICAL BIOLOGY, 2017, 24 (01): : 9 - 23
[25] Discovery Small-Molecule p300 Inhibitors Derived from a Newly Developed Indazolone-Focused DNA-Encoded Library
Suo, Yanrui
Li, Kaige
Ling, Xing
Yan, Kenian
Lu, Weiwei
Yue, Jinfeng
Chen, Xiaohua
Duan, Zhiqiang
Lu, Xiaojie
BIOCONJUGATE CHEMISTRY, 2024, 35 (08) : 1251 - 1257
[26] Evaluation of AU-18069, a novel small molecule CBP/p300 bromodomain inhibitor for the treatment of cancers
Abbineni, Chandrasekhar
Thiyagarajan, Saravanan
Aravind, A. B.
Dhudashiya, Amit A.
Marappan, Sivapriya
Kumar, Naveen R.
Raghavendra, N. R.
Dey, Mamon
Kumar, Avinash
Bharathi, Uma B., V
Renukappa, Girish Aggunda
Reddy, N. Venkata Siva
Babu, Asha
Shetty, Aakanksha J.
Amith, A.
Rao, Narasimha K.
Gore, Suraj T.
Jaleel, Mahaboobi
Senaiar, Ramesh S.
Nataraj, Vijaya Shankar
Mukherjee, Subhendu
Samiulla, D. S.
Antony, Thomas
Daginakatte, Girish
Eswarappa, Rajesh
Nellore, Kavitha
Chelur, Shekar
Ramachandra, Murali
Samajdar, Susanta
CANCER RESEARCH, 2022, 82 (12)
[27] The important role of the histone acetyltransferases p300/CBP in cancer and the promising anticancer effects of p300/CBP inhibitors
Wu, Xin
Zhang, Xin
Tang, Shaoshan
Wang, Yao
CELL BIOLOGY AND TOXICOLOGY, 2025, 41 (01)
[28] HAT Trick: p300, Small Molecule, Inhibitor
Ott, Melanie
Verdin, Eric
CHEMISTRY & BIOLOGY, 2010, 17 (05): : 417 - 418
[29] Small molecule modulators of histone acetyltransferase p300
Balasubramanyam, K
Swaminathan, V
Ranganathan, A
Kundu, TK
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (21) : 19134 - 19140
[30] p300/CBP keeps chromatin silent
Wrighton, Katharine H.
NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2022, 29 (11) : 1039 - 1039

← 1 2 3 4 5 →